Home » AEGERA INITIATES CLINICAL TRIAL FOR AEG35156
AEGERA INITIATES CLINICAL TRIAL FOR AEG35156
Aegera Therapeutics has announced the initiation of its third human clinical study for AEG35156, the company's proprietary therapeutic targeting the X-linked Inhibitor of Apoptosis Protein (XIAP), a key regulator of apoptosis. This Phase I trial is an open-label study of AEG35156 administered in combination with ara-C and idarubicin in patients with refractory or relapsed acute myeloid leukemia (AML).
The trial is being conducted at two leading North American cancer centers: the University of Texas M. D. Anderson Cancer Center in Houston, Texas; and Princess Margaret Hospital, part of University Health Network in Toronto, Ontario. It is designed to find an effective and safe dose to treat leukemia patients.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May